Valuation : Nipro Corporation

Market Cap 253B 1.6B 1.38B 1.3B 1.18B 2.21B 151B 2.22B 15.35B 5.96B 77.04B 5.99B 5.86B P/E 2027 *
15.7x
P/E 2028 * 11.9x
Enterprise Value 754B 4.75B 4.1B 3.86B 3.52B 6.58B 449B 6.63B 45.72B 17.75B 230B 17.85B 17.46B EV / Sales 2027 *
1.08x
EV / Sales 2028 * 1.02x
Free-Float
84.43%
Yield 2027 *
2.36%
Yield 2028 * 2.96%
07-30 Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United States CI
07-28 Vat Holding AG agreed to acquire 100% stake in Atonarp Inc. from Nipro Corporation for CHF 110 million. CI
07-14 Jefferies Adjusts Nipro's Price Target to 1,700 Yen From 1,500 Yen, Keeps at Hold MT
05-12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
05-12 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
05-01 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
03-11 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
02-08 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12-24 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
11-10 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
25-06-10 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
25-06-09 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
25-05-13 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
1 day-1.02%
1 week-1.63%
Current month-1.95%
1 month-6.31%
3 months-13.09%
6 months-4.92%
Current year+2.03%
1 week 1,506
Extreme 1506
1,553
1 month 1,506
Extreme 1506
1,684.5
Current year 1,401
Extreme 1401
1,760.5
1 year 1,401
Extreme 1401
1,760.5
3 years 1,041
Extreme 1041
1,760.5
5 years 987
Extreme 987
1,760.5
10 years 908
Extreme 908
1,760.5
Manager TitleAgeSince
Director of Finance/CFO 57 2025-05-31
President 58 2025-05-31
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 81 2025-06-25
Director/Board Member 53 2009-05-31
Director/Board Member 58 2009-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.99%-1.63%-1.89%+23.22% 1.61B
+1.41%-3.18%-15.97%+7.41% 188B
+0.15%+0.17%-1.23%+12.24% 118B
+1.63%+2.61%+14.08%+92.25% 63.16B
-1.62%-1.92%+22.89%+45.95% 52.01B
+0.21%-1.41%-0.33%-32.66% 50.97B
-0.50%+0.82%+20.71%-11.98% 34.02B
+3.39%+4.97% - - 30.8B
+1.18%-2.08%+40.57%-15.96% 23.83B
+0.24%-3.36%-6.00%+13.90% 23.45B
Average +0.44%-0.59%+8.09%+14.93% 58.62B
Weighted average by Cap. +0.63%-1.72%+0.78%+16.14%

Financials

2027 *2028 *
Net sales 701B 4.42B 3.81B 3.59B 3.27B 6.12B 417B 6.16B 42.52B 16.5B 213B 16.59B 16.23B 729B 4.59B 3.96B 3.73B 3.4B 6.36B 434B 6.41B 44.2B 17.15B 222B 17.25B 16.87B
Net income 15.39B 97.02M 83.7M 78.85M 71.84M 134M 9.17B 135M 934M 362M 4.69B 364M 356M 19.95B 126M 108M 102M 93.12M 174M 11.88B 175M 1.21B 470M 6.07B 472M 462M
Net Debt 501B 3.16B 2.72B 2.57B 2.34B 4.37B 298B 4.4B 30.38B 11.79B 152B 11.86B 11.6B 489B 3.08B 2.66B 2.51B 2.28B 4.27B 291B 4.3B 29.67B 11.51B 149B 11.58B 11.33B
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
38,593
Date Price Change Volume
26-09-02 JP¥1,507.50 -0.99% 198,800
26-09-02 JP¥1,522.50 -1.96% 720,600
26-09-01 JP¥1,553.00 +1.04% 620,200
26-08-31 JP¥1,537.00 +0.59% 713,600
26-08-28 JP¥1,528.00 -0.26% 797,600
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,522.50JPY
Average target price
1,996.00JPY
Spread / Average Target
+31.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 8086 Stock